10-Q: Recursion Pharmaceuticals Reports Q1 2025 Results, Highlights Pipeline Progress and Strategic Partnerships

Recursion Pharmaceuticals announces its Q1 2025 financial results, showcasing advancements in its pipeline and ongoing collaborations.

Summary

• Recursion Pharmaceuticals reported a net loss of $202.5 million for the three months ended March 31, 2025, compared to a net loss of $91.4 million for the same period in 2024.
• The company's operating revenue increased to $14.8 million from $13.5 million year-over-year.
• Research and development expenses significantly increased to $129.6 million from $67.6 million year-over-year, driven by platform development, the Exscientia acquisition, and personnel costs.
• General and administrative expenses also rose to $54.7 million from $31.4 million year-over-year, influenced by the Exscientia acquisition and increased salaries.
• The company highlighted progress in its pipeline, including preliminary data from the REC-4881 study in familial adenomatous polyposis (FAP) showing a median 43% reduction in polyp burden in a small patient sample.
• Strategic partnerships with Sanofi and Roche continue to advance, with Sanofi achieving a milestone resulting in a $7 million payment to Recursion.
• The company is discontinuing development of REC-2282 (NF2) and REC-994 (CCM) due to futility and lack of promising trends, respectively, and will consider out-licensing REC-3964 (C. difficile).
• Recursion had cash and cash equivalents of $500.5 million as of March 31, 2025, and believes this is sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there's progress in partnerships and some pipeline programs, the increased net loss and discontinuation of certain programs temper the positive aspects.

Positives

• Operating revenue increased by 10% year-over-year, indicating growth in strategic partnerships.
• Preliminary data from the REC-4881 study showed promising results in reducing polyp burden in FAP patients.
• Advancement of the Sanofi partnership resulted in a $7 million milestone payment.
• The company believes its current cash and cash equivalents are sufficient to fund operations for at least the next 12 months.
• The company is expanding its ClinTech focus including high-quality, linked data assets, to industrialize clinical development, reduce costs, and accelerate the development of novel therapeutics.

Negatives

• Net loss significantly increased to $202.5 million, compared to $91.4 million in the same period last year.
• Research and development expenses have increased significantly, impacting overall profitability.
• The company is discontinuing development of REC-2282 (NF2) and REC-994 (CCM) due to unfavorable data, indicating setbacks in the pipeline.
• The company recorded a loss on the disposal of Exscientia GmbH of $4.5 million.

Risks

• The company has a history of operating losses and expects to incur substantial operating losses in the future.
• The company will require additional capital to advance its drug candidates and may not be able to obtain it on favorable terms or at all.
• Clinical trial outcomes are uncertain, and drug development milestones may not be achieved.
• The company faces risks related to intellectual property protection and potential disputes.
• The company is subject to various governmental export controls, trade and economic sanctions, and import laws and regulations that could impair our ability to compete in international markets and subject us to liability if we are not in full compliance with applicable laws.
• The company's disclosure controls and procedures were ineffective due to the material weakness in internal control over financial reporting.

Future Outlook

Recursion believes its existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures for at least the next 12 months. The company anticipates needing additional financing in the future.

Industry Context

Recursion operates in the competitive TechBio industry, leveraging AI and machine learning to accelerate drug discovery. The company's partnerships with major pharmaceutical companies like Sanofi, Roche, and Merck KGaA highlight the industry's growing interest in AI-driven drug development. The company is discontinuing development of REC-2282 (NF2) and REC-994 (CCM) due to unfavorable data, indicating setbacks in the pipeline.

Comparison to Industry Standards

• It's difficult to directly compare Recursion's financial results to industry standards without knowing the specific benchmarks for TechBio companies at a similar stage of development.
• However, the increase in R&D spending is typical for companies advancing multiple clinical and preclinical programs.
• The net loss is substantial, but not uncommon for biotech companies investing heavily in research and development.
• The company's cash position is relatively strong, providing a runway for continued operations and development.

Legal Proceedings

• The company is involved in a putative class action complaint filed against Exscientia plc and certain officers, alleging violations of federal securities laws.
• The company is also involved in a lawsuit with Industry Office SLC, LLC regarding a lease agreement for laboratory and office space.

Stakeholder Impact

• Shareholders: The increased net loss may negatively impact shareholder value, but pipeline progress and partnerships could offer future potential.
• Employees: Discontinuation of certain programs may lead to restructuring or reallocation of resources.
• Customers/Partners: Continued collaboration and advancement of programs benefit partners, while discontinuation of programs may impact existing agreements.
• Creditors: The company's cash position provides stability for meeting financial obligations.

Next Steps

• Initiate CDK7 combination studies in 1H25 and expect additional monotherapy data in 2H25.
• Expect additional data in FAP from TUPELO in 2H25.
• Continue preclinical studies for REC-7735 (PI3K H1047R) with a development candidate expected in 2H25.
• Expect early Phase 1 safety and PK monotherapy data for REC-1245 (RBM39) in 1H26.
• Expect early Phase 1 safety and PK monotherapy data for REC-3565 (MALT1) in 2H26.
• Expect Phase 1 initiation for REV102 (ENPP1) in 2H26.

Key Dates

Keywords

Recursion Pharmaceuticals, financial results, pipeline, partnerships, drug discovery, AI, clinical trials, net loss, revenue, R&D, Exscientia, Sanofi, Roche, REC-4881, FAP